Observational studyFrontiers in neurology2026
Clinical features associated with cerebrospinal fluid Epstein-Barr virus positivity in autoimmune GFAP astrocytopathy: a multicenter retrospective cohort study.
Observational study in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is an inflammatory disorder of the central nervous system. The clinical implications of Epstein-Barr virus (EBV) sequences detected in cerebrospinal fluid (CSF) by metagenomic next-generation sequencing (mNGS) remain uncertain. Methods: This multicenter retrospective cohort study enrolled 60 patients with GFAP-A screened from electronic medical records of two hospitals (Jan 2019-Dec 2025). Patients were stratified into CSF EBV-positive ( Results: CSF WBC count was higher in the CSF EBV-positive group than in the CSF EBV-negative group [median, 120 (interquartile range, 105-220) vs. 33 (16-97) × 10⁶/L; raw Conclusion: CSF WBC count was the only clinically prioritized comparison that remained statistically significant after Bonferroni correction, suggesting greater CSF pleocytosis and possibly increased intrathecal inflammatory activity in GFAP-A patients with mNGS-detectable CSF EBV. Differences in altered consciousness and CSF chloride remained inconclusive after multiplicity adjustment. Within the EBV-positive subgroup, raw EBV sequencing reads showed no correlation with inflammatory or disability measures. Current findings do not establish CSF EBV positivity as an independent pathogenic or prognostic biomarker for GFAP-A, and the biological origin of the detected EBV sequences remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.